IL1B and irritable bowel syndrome: Supporting this therapeutic avenue, IL-1 signaling inhibition has yielded positive outcomes in individual UC cases [304], while IL-1-driven stromal-neutrophil interactions characterize a subset of IBD patients refractory to conventional treatments [239].